Xylem (XYL) Stock Forecast, Price Target & Predictions
XYL Stock Forecast
Xylem stock forecast is as follows: an average price target of $141.83 (represents a 8.41% upside from XYL’s last price of $130.83) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
XYL Price Target
The average price target for Xylem (XYL) is $141.83 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $170.00 to $107.00. This represents a potential 8.41% upside from XYL's last price of $130.83.
XYL Analyst Ratings
According to 14 Wall Street analysts, Xylem's rating consensus is 'Buy'. The analyst rating breakdown for XYL stock is 0 'Strong Buy' (0.00%), 8 'Buy' (57.14%), 5 'Hold' (35.71%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).
Xylem Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Damian Karas | UBS | $165.00 | $127.50 | 29.41% | 26.12% |
| Jul 31, 2024 | Michael Halloran | Robert W. Baird | $170.00 | $133.48 | 27.36% | 29.94% |
| May 31, 2024 | Bryan Blair | Oppenheimer | $152.00 | $139.40 | 9.04% | 16.18% |
| May 29, 2024 | John Eade | Argus Research | $165.00 | $140.36 | 17.55% | 26.12% |
| May 03, 2024 | Brett Linzey | Mizuho Securities | $135.00 | $135.99 | -0.73% | 3.19% |
| May 03, 2024 | Deane Dray | RBC Capital | $162.00 | $135.99 | 19.13% | 23.82% |
| May 03, 2024 | Michael Halloran | Robert W. Baird | $155.00 | $135.99 | 13.98% | 18.47% |
| Apr 08, 2024 | Brad Hewitt | Wolfe Research | $143.00 | $128.27 | 11.48% | 9.30% |
| Apr 04, 2024 | Deane Dray | RBC Capital | $153.00 | $127.25 | 20.24% | 16.95% |
| Aug 18, 2023 | Nathan Jones | Stifel Nicolaus | $133.00 | $99.80 | 33.27% | 1.66% |
The latest Xylem stock forecast, released on Aug 13, 2024 by Damian Karas from UBS, set a price target of $165.00, which represents a 29.41% increase from the stock price at the time of the forecast ($127.50), and a 26.12% increase from XYL last price ($130.83).
Xylem Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 9 |
| Avg Price Target | - | $167.50 | $155.56 |
| Last Closing Price | $130.83 | $130.83 | $130.83 |
| Upside/Downside | -100.00% | 28.03% | 18.90% |
In the current month, the average price target of Xylem stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Xylem's last price of $130.83. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Cowen & Co. | Buy | Hold | Downgrade |
| Aug 13, 2024 | UBS | - | Buy | Initialise |
| Jun 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 31, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 28, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 03, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 08, 2024 | Citigroup | Neutral | Neutral | Hold |
| Apr 08, 2024 | Wolfe Research | Outperform | Outperform | Hold |
| Apr 04, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Nov 21, 2023 | Deutsche Bank | - | Buy | Upgrade |
Xylem's last stock rating was published by Cowen & Co. on Sep 03, 2024. The company Downgrade its XYL rating from "Buy" to "Hold".
Xylem Financial Forecast
Xylem Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.12B | - | $1.72B | $1.45B | $1.51B | $1.38B | - | $1.27B | $1.32B | $1.26B | $1.35B | $1.26B | $1.37B | $1.22B |
| Avg Forecast | $2.53B | $2.48B | $2.47B | $2.32B | $2.47B | $2.42B | $2.41B | $2.25B | $2.35B | $2.30B | $2.27B | $2.13B | $2.21B | $2.17B | $2.14B | $2.00B | $2.05B | $1.99B | $1.49B | $1.35B | $1.41B | $1.34B | $1.32B | $1.24B | $1.31B | $1.29B | $1.31B | $1.17B | $1.29B | $1.16B |
| High Forecast | $2.55B | $2.50B | $2.49B | $2.34B | $2.49B | $2.44B | $2.43B | $2.27B | $2.37B | $2.31B | $2.29B | $2.15B | $2.23B | $2.18B | $2.16B | $2.01B | $2.07B | $2.04B | $1.50B | $1.36B | $1.42B | $1.35B | $1.32B | $1.26B | $1.34B | $1.32B | $1.34B | $1.20B | $1.32B | $1.18B |
| Low Forecast | $2.51B | $2.47B | $2.46B | $2.30B | $2.46B | $2.40B | $2.39B | $2.24B | $2.33B | $2.28B | $2.26B | $2.12B | $2.19B | $2.16B | $2.13B | $1.98B | $2.03B | $1.93B | $1.48B | $1.34B | $1.40B | $1.33B | $1.32B | $1.21B | $1.28B | $1.26B | $1.28B | $1.15B | $1.26B | $1.13B |
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | - | 1.16% | 1.08% | 1.07% | 1.03% | - | 1.03% | 1.01% | 0.98% | 1.03% | 1.07% | 1.06% | 1.05% |
Xylem's average Quarter revenue forecast for Mar 24 based on 3 analysts is $2.00B, with a low forecast of $1.98B, and a high forecast of $2.01B. XYL's average Quarter revenue forecast represents a -5.76% decrease compared to the company's last Quarter revenue of $2.12B (Dec 23).
Xylem EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $266.00M | $152.00M | $246.00M | $203.00M | $269.00M | $102.00M | - | $168.00M | $198.00M | $216.00M | $221.00M | $197.00M | $241.00M | $135.00M |
| Avg Forecast | $400.07M | $392.66M | $391.10M | $366.37M | $391.23M | $382.60M | $380.47M | $356.40M | $371.10M | $362.94M | $359.24M | $337.48M | $349.38M | $343.78M | $339.08M | $148.17M | $324.70M | $314.65M | $235.24M | $134.70M | $223.33M | $221.49M | $208.04M | $122.45M | $191.51M | $201.36M | $210.48M | $114.05M | $194.93M | $105.88M |
| High Forecast | $403.38M | $395.91M | $394.35M | $369.41M | $394.48M | $385.78M | $383.63M | $359.36M | $374.18M | $365.95M | $362.22M | $340.28M | $352.28M | $345.37M | $341.89M | $177.80M | $327.86M | $322.56M | $237.19M | $161.64M | $225.19M | $265.79M | $208.04M | $146.94M | $229.81M | $241.63M | $252.57M | $136.86M | $233.91M | $127.06M |
| Low Forecast | $397.40M | $390.04M | $388.50M | $363.93M | $388.63M | $380.06M | $377.94M | $354.03M | $368.63M | $360.53M | $356.85M | $335.23M | $347.06M | $341.49M | $336.82M | $118.53M | $321.53M | $305.46M | $233.68M | $107.76M | $221.85M | $177.19M | $208.04M | $97.96M | $153.21M | $161.08M | $168.38M | $91.24M | $155.94M | $84.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 0.48% | 1.05% | 1.51% | 1.20% | 0.46% | - | 1.37% | 1.03% | 1.07% | 1.05% | 1.73% | 1.24% | 1.28% |
3 analysts predict XYL's average Quarter EBITDA for Mar 24 to be $148.17M, with a high of $177.80M and a low of $118.53M. This is -44.30% lower than Xylem's previous annual EBITDA (Dec 23) of $266.00M.
Xylem Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $266.00M | $152.00M | $92.00M | $99.00M | $149.00M | $12.00M | - | $82.00M | $113.00M | $114.00M | $113.00M | $87.00M | $148.00M | $37.00M |
| Avg Forecast | $365.82M | $359.36M | $350.55M | $299.75M | $349.71M | $346.09M | $329.13M | $281.09M | $316.59M | $306.50M | $291.09M | $249.16M | $281.12M | $269.84M | $256.14M | $87.41M | $232.69M | $215.76M | $198.75M | $79.46M | $193.11M | $116.90M | $130.64M | $72.24M | $109.30M | $106.27M | $107.62M | $50.37M | $119.71M | $29.02M |
| High Forecast | $369.76M | $363.24M | $354.33M | $302.98M | $353.48M | $349.83M | $332.69M | $284.12M | $320.01M | $309.81M | $294.23M | $251.85M | $284.16M | $272.27M | $258.91M | $104.89M | $242.39M | $223.03M | $200.90M | $95.35M | $195.20M | $140.28M | $130.64M | $86.69M | $131.15M | $127.53M | $129.14M | $60.44M | $143.65M | $34.82M |
| Low Forecast | $362.65M | $356.26M | $347.52M | $297.16M | $346.68M | $343.10M | $326.29M | $278.66M | $313.85M | $303.85M | $288.57M | $247.00M | $278.69M | $267.41M | $253.93M | $69.93M | $223.00M | $208.49M | $197.03M | $63.57M | $191.44M | $93.52M | $130.64M | $57.79M | $87.44M | $85.02M | $86.10M | $40.29M | $95.76M | $23.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 0.70% | 0.46% | 1.25% | 0.77% | 0.10% | - | 1.14% | 1.03% | 1.07% | 1.05% | 1.73% | 1.24% | 1.28% |
Xylem's average Quarter net income forecast for Mar 24 is $87.41M, with a range of $69.93M to $104.89M. XYL's average Quarter net income forecast represents a -67.14% decrease compared to the company's last Quarter net income of $266.00M (Dec 23).
Xylem SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $446.00M | $354.00M | $315.00M | $294.00M | - | $304.00M | $301.00M | $273.00M | $304.00M | $301.00M | $292.00M | $266.00M |
| Avg Forecast | $578.23M | $567.52M | $565.27M | $529.53M | $565.46M | $552.99M | $549.91M | $515.12M | $536.36M | $524.57M | $519.22M | $487.77M | $504.98M | $496.88M | $490.08M | $324.05M | $469.30M | $454.77M | $340.00M | $294.59M | $322.79M | $279.94M | $300.69M | $267.81M | $291.13M | $254.49M | $289.52M | $174.26M | $-843.60M | $208.63M |
| High Forecast | $583.03M | $572.23M | $569.96M | $533.92M | $570.16M | $557.58M | $554.47M | $519.39M | $540.81M | $528.92M | $523.52M | $491.82M | $509.17M | $499.17M | $494.15M | $388.86M | $473.87M | $466.21M | $342.82M | $353.51M | $325.47M | $335.93M | $300.69M | $321.37M | $349.36M | $305.39M | $347.43M | $209.12M | $-674.88M | $250.35M |
| Low Forecast | $574.38M | $563.74M | $561.51M | $526.00M | $561.70M | $549.31M | $546.25M | $511.69M | $532.79M | $521.08M | $515.76M | $484.52M | $501.62M | $493.57M | $486.82M | $259.24M | $464.72M | $441.49M | $337.74M | $235.67M | $320.64M | $223.95M | $300.69M | $214.25M | $232.90M | $203.59M | $231.62M | $139.41M | $-1.01B | $166.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.31% | 1.20% | 0.98% | 1.05% | - | 1.14% | 1.03% | 1.07% | 1.05% | 1.73% | -0.35% | 1.28% |
Xylem's average Quarter SG&A projection for Sep 23 is $454.77M, based on 13 Wall Street analysts, with a range of $441.49M to $466.21M. The forecast indicates a 1.97% rise compared to XYL last annual SG&A of $446.00M (Jun 23).
Xylem EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.10 | - | $0.45 | $0.55 | $0.83 | $0.07 | - | $0.45 | $0.63 | $0.63 | $0.63 | $0.49 | $0.82 | $0.20 |
| Avg Forecast | $1.50 | $1.48 | $1.44 | $1.23 | $1.44 | $1.42 | $1.35 | $1.15 | $1.30 | $1.26 | $1.20 | $1.02 | $1.15 | $1.11 | $1.05 | $0.84 | $0.96 | $0.89 | $0.82 | $0.62 | $0.79 | $0.66 | $0.54 | $0.41 | $0.61 | $0.59 | $0.63 | $0.38 | $0.69 | $0.51 |
| High Forecast | $1.52 | $1.49 | $1.45 | $1.24 | $1.45 | $1.44 | $1.37 | $1.17 | $1.31 | $1.27 | $1.21 | $1.03 | $1.17 | $1.12 | $1.06 | $0.85 | $1.00 | $0.92 | $0.82 | $0.62 | $0.80 | $0.67 | $0.54 | $0.42 | $0.63 | $0.61 | $0.64 | $0.39 | $0.71 | $0.52 |
| Low Forecast | $1.49 | $1.46 | $1.43 | $1.22 | $1.42 | $1.41 | $1.34 | $1.14 | $1.29 | $1.25 | $1.18 | $1.01 | $1.14 | $1.10 | $1.04 | $0.83 | $0.92 | $0.86 | $0.81 | $0.61 | $0.79 | $0.65 | $0.54 | $0.40 | $0.59 | $0.57 | $0.61 | $0.36 | $0.67 | $0.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 0.00% | 0.55% | 0.89% | 1.05% | 0.11% | - | 1.09% | 1.03% | 1.06% | 1.01% | 1.31% | 1.19% | 0.40% |
According to 3 Wall Street analysts, Xylem's projected average Quarter EPS for Mar 24 is $0.84, with a low estimate of $0.83 and a high estimate of $0.85. This represents a -23.77% decrease compared to XYL previous annual EPS of $1.10 (Dec 23).
Xylem Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IEX | IDEX | $199.78 | $236.33 | 18.30% | Buy |
| EMR | Emerson Electric | $102.03 | $116.55 | 14.23% | Buy |
| AOS | A. O. Smith | $79.97 | $87.67 | 9.63% | Buy |
| XYL | Xylem | $130.83 | $141.83 | 8.41% | Buy |
| FELE | Franklin Electric | $97.16 | $103.00 | 6.01% | Buy |
| FLS | Flowserve | $46.65 | $48.00 | 2.89% | Buy |
| DOV | Dover | $185.06 | $175.22 | -5.32% | Hold |
| PNR | Pentair | $91.49 | $86.54 | -5.41% | Buy |
| ITT | ITT | $135.35 | $124.50 | -8.02% | Buy |
| ITW | Illinois Tool Works | $251.75 | $230.92 | -8.27% | Hold |
| PH | Parker-Hannifin | $591.33 | $517.79 | -12.44% | Buy |
| IR | Ingersoll Rand | $91.03 | $70.33 | -22.74% | Buy |
| ETN | Eaton | $305.80 | $227.70 | -25.54% | Buy |
XYL Forecast FAQ
Is Xylem a good buy?
Yes, according to 14 Wall Street analysts, Xylem (XYL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 57.14% of XYL's total ratings.
What is XYL's price target?
Xylem (XYL) average price target is $141.83 with a range of $107 to $170, implying a 8.41% from its last price of $130.83. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Xylem stock go up soon?
According to Wall Street analysts' prediction for XYL stock, the company can go up by 8.41% (from the last price of $130.83 to the average price target of $141.83), up by 29.94% based on the highest stock price target, and down by -18.21% based on the lowest stock price target.
Can Xylem stock reach $200?
XYL's average twelve months analyst stock price target of $141.83 does not support the claim that Xylem can reach $200 in the near future.
What are Xylem's analysts' financial forecasts?
Xylem's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.55B (high $9.63B, low $9.49B), average EBITDA is $1.51B (high $1.52B, low $1.5B), average net income is $1.31B (high $1.32B, low $1.29B), average SG&A $2.18B (high $2.2B, low $2.17B), and average EPS is $5.36 (high $5.42, low $5.32). XYL's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $9.8B (high $9.89B, low $9.74B), average EBITDA is $1.55B (high $1.56B, low $1.54B), average net income is $1.38B (high $1.39B, low $1.36B), average SG&A $2.24B (high $2.26B, low $2.23B), and average EPS is $5.65 (high $5.71, low $5.6).
Did the XYL's actual financial results beat the analysts' financial forecasts?
Based on Xylem's last annual report (Dec 2023), the company's revenue was $7.36B, beating the average analysts forecast of $6.88B by 7.07%. Apple's EBITDA was $1.16B, beating the average prediction of $1.01B by 15.33%. The company's net income was $609M, missing the average estimation of $726.67M by -16.19%. Apple's SG&A was $1.76B, beating the average forecast of $1.56B by 12.72%. Lastly, the company's EPS was $2.79, missing the average prediction of $3.28 by -14.83%. In terms of the last quarterly report (Dec 2023), Xylem's revenue was $2.12B, beating the average analysts' forecast of $2.05B by 3.14%. The company's EBITDA was $266M, missing the average prediction of $324.7M by -18.08%. Xylem's net income was $266M, beating the average estimation of $232.69M by 14.31%. The company's SG&A was $0, missing the average forecast of $469.3M by -100.00%. Lastly, the company's EPS was $1.1, beating the average prediction of $0.955 by 15.13%